Positron emission tomography to elucidate pharmacokinetic differences of regioisomeric retinoid x receptor agonists

ACS Medicinal Chemistry Letters

Volumn 6, Issue 3, 2015, Pages 334-338

  Kobayashi, Toshiki ^a   Furusawa, Yuki ^a   Yamada, Shoya ^a,b   Akehi, Masaru ^a   Takenaka, Fumiaki ^a   Sasaki, Takanori ^a   Akahoshi, Akiya ^a   Hanada, Takahisa ^a   Matsuura, Eiji ^a   Hirano, Hiroyuki ^c   Tai, Akihiro ^d   Kakuta, Hiroki ^a  

^a OKAYAMA UNIVERSITY   (Japan)

^b JAPAN SOCIETY FOR THE PROMOTION OF SCIENCE   (Japan)

^c Japan   (Japan)

^d PREFECTURAL UNIVERSITY OF HIROSHIMA   (Japan)

Author keywords

Nuclear receptors; PET imaging; pharmacokinetics; RXR

Indexed keywords

6 [ETHYL (3 ISOBUTOXY 4 ISOPROPYLPHENYL)AMINO]PYRIDINE 3 CARBOXYLIC ACID]; 6 [ETHYL (4 ISOBUTOXY 3 ISOPROPYLPHENYL)AMINO]PYRIDINE 3 CARBOXYLIC ACID; BEXAROTENE; CARBON 11; FLUORINE 18; PARTIAL AGONIST; RETINOID X RECEPTOR; RETINOID X RECEPTOR AGONIST; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; ANIMAL CELL; ANIMAL EXPERIMENT; ANTIDIABETIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; BILIARY EXCRETION; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG DISTRIBUTION; DRUG EXCRETION; DRUG METABOLISM; EC50; ENTEROHEPATIC CIRCULATION; HYDROPHOBICITY; INTESTINE ABSORPTION; LIPOPHILICITY; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PARKINSON DISEASE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL;

MUS;

EID: 84924744768     PISSN: None     EISSN: 19485875     Source Type: Journal    
DOI: 10.1021/ml500511m     Document Type: Article

References (21)

1. Pileri, A.; Delfino, C.; Grandi, V.; Pimpinelli, N. Role of bexarotene in the treatment of cutaneous T-cell lymphoma: the clinical and immunological sides Immunotherapy 2013, 5, 427-433
2. Mukherjee, R.; Davies, P. J.; Crombie, D. L.; Bischoff, E. D.; Cesario, R. M.; Jow, L.; Hamann, L. G.; Boehm, M. F.; Mondon, C. E.; Nadzan, A. M.; Paterniti, J. R., Jr.; Heyman, R. A. Sensitization of diabetic and obese mice to insulin by retinoid X receptor agonists Nature 1997, 386, 407-410
3. Cramer, P. E.; Cirrito, J. R.; Wesson, D. W.; Lee, C. Y.; Karlo, J. C.; Zinn, A. E.; Casali, B. T.; Restivo, J. L.; Goebel, W. D.; James, M. J.; Brunden, K. R.; Wilson, D. A.; Landreth, G. E. ApoE-directed therapeutics rapidly clear β-amyloid and reverse deficits in AD mouse models Science 2012, 335, 1503-1506
4. McFarland, K.; Spalding, T. A.; Hubbard, D.; Ma, J. N.; Olsson, R.; Burstein, E. S. Low dose bexarotene treatment rescues dopamine neurons and restores behavioral function in models of Parkinsons disease ACS Chem. Neurosci. 2013, 4, 1430-1438
5. Sherman, S. I. Etiology, diagnosis, and treatment recommendations for central hypothyroidism associated with bexarotene therapy for cutaneous T-cell lymphoma Clin. Lymphoma 2003, 3, 249-252
6. Lenhard, J. M.; Lancaster, M. E.; Paulik, M. A.; Weiel, J. E.; Binz, J. G.; Sundseth, S. S.; Gaskill, B. A.; Lightfoot, R. M.; Brown, H. R. The RXR agonist LG100268 causes hepatomegaly, improves glycaemic control and decreases cardiovascular risk and cachexia in diabetic mice suffering from pancreatic beta-cell dysfunction Diabetologia 1999, 42, 545-554
7. Standeven, A. M.; Escobar, M.; Beard, R. L.; Yuan, Y. D.; Chandraratna, R. A. Mitogenic effect of retinoid X receptor agonists in rat liver Biochem. Pharmacol. 1997, 54, 517-524
8. Standeven, A. M.; Thacher, S. M.; Yuan, Y. D.; Escobar, M.; Vuligonda, V.; Beard, R. L.; Chandraratna, R. A. Retinoid X receptor agonist elevation of serum triglycerides in rats by potentiation of retinoic acid receptor agonist induction or by action as single agents Biochem. Pharmacol. 2001, 62, 1501-1509
9. de Vries-van der Weij, J.; de Haan, W.; Hu, L.; Kuif, M.; Oei, H. L.; van der Hoorn, J. W.; Havekes, L. M.; Princen, H. M.; Romijn, J. A.; Smit, J. W.; Rensen, P. C. Bexarotene induces dyslipidemia by increased very low-density lipoprotein production and cholesteryl ester transfer protein-mediated reduction of high-density lipoprotein Endocrinology 2009, 150, 2368-2375
10. Takamatsu, K.; Takano, A.; Yakushij, N.; Morohashi, K.; Morishita, K.; Matsuura, N.; Makishima, M.; Tai, A.; Sasaki, K.; Kakuta, H. The first potent subtype-selective retinoid X receptor (RXR) agonist possessing a 3-isopropoxy-4-isopropylphenylamino moiety, NEt-3IP (RXRα/β-dual agonist) ChemMedChem 2008, 3, 780-787
11. Ohsawa, F.; Morishita, K.; Yamada, S.; Makishima, M.; Kakuta, H. Modification at the lipophilic domain of RXR agonists differentially influences activation of RXR heterodimers ACS Med. Chem. Lett. 2010, 1, 521-525
12. Kawata, K.; Morishita, K.; Nakayama, M.; Yamada, S.; Kobayashi, T.; Furusawa, Y.; Arimoto-Kobayashi, S.; Oohashi, T.; Makishima, M.; Naitou, H.; Ishitsubo, E.; Tokiwa, H.; Tai, A.; Kakuta, H. RXR partial agonist produced by side chain repositioning of alkoxy RXR full agonist retains antitype 2 diabetes activity without the adverse effects J. Med. Chem. 2014, x 10.1021/jm501863r
13. Bergström, M.; Grahnen, A.; Långström, B. Positron emission tomography microdosing: a new concept with application in tracer and early clinical drug development Eur. J. Clin. Pharmacol. 2003, 59, 357-366
14. Fischman, A. J.; Alpert, N. M.; Rubin, R. H. Pharmacokinetic imaging: a noninvasive method for determining drug distribution and action Clin. Pharmacokinet. 2002, 41, 581-602
15. 11C]carbon dioxide fixation and preliminary PET imaging ACS Med. Chem. Lett. 2014, 6, 668-672
16. Van der Mey, M.; Janssen, C. G.; Janssens, F. E.; Jurzak, M.; Langlois, X.; Sommen, F. M.; Verreet, B.; Windhorst, A. D.; Leysen, J. E.; Herscheid, J. D. Synthesis and biodistribution of [(11)C]R116301, a promising PET ligand for central NK(1) receptors Bioorg. Med. Chem. 2005, 13, 1579-1586
17. 18F]-fluoro-2-deoxy-D-glucose using aminopolyether supported nucleophilic substitution J. Nucl. Med. 1986, 27, 235-238
18. Böhm, H. J.; Banner, D.; Bendels, S.; Kansy, M.; Kuhn, B.; Müller, K.; Obst-Sander, U.; Stahl, M. Fluorine in medicinal chemistry ChemBioChem 2004, 5, 637-643
19. Lipinski, C. A.; Lombardo, F.; Dominy, B. W.; Feeney, P. J. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings Adv. Drug Delivery Rev. 2001, 46, 3-26
20. Yamashita, S.; Takashima, T.; Kataoka, M.; Oh, H.; Sakuma, S.; Takahashi, M.; Suzuki, N.; Hayashinaka, E.; Wada, Y.; Cui, Y.; Watanabe, Y. PET imaging of the gastrointestinal absorption of orally administered drugs in conscious and anesthetized rats J. Nucl. Med. 2011, 52, 249-256
21. Landreth, G. E.; Cramer, P. E.; Lakner, M. M.; Cirrito, J. R.; Wesson, D. W.; Brunden, K. R.; Wilson, D. A. Response to comments on "ApoE-directed therapeutics rapidly clear β-amyloid and reverse deficits in AD mouse models" Science 2013, 340, 924-g